Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides

Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):905-10. doi: 10.1161/01.ATV.0000067700.77438.3F. Epub 2003 Mar 20.

Abstract

Objective: This study was performed to evaluate the mechanisms leading to tumor vessel occlusion by tissue factor-based drugs, which are used in vascular targeting approaches for the treatment of malignant tumors.

Methods and results: The effects of nontargeted soluble tissue factor were evaluated in vitro and in vivo. Tumor-bearing mice were treated with (1) the extracellular portion of tissue factor (soluble tissue factor), (2) low nontoxic doses of lipopolysaccharides, or (3) a combination thereof. The combination treatment showed the best effects and resulted in selective thrombosis of tumor vessels. On the basis of our data from subsequent in vitro analyses, including surface plasmon resonance measurements and endothelial cell based coagulation assays, we propose a model on how soluble tissue factor, although lacking its membrane anchor, can promote selective tumor vessel occlusion.

Conclusions: To our knowledge, this is the first report to describe the molecular mechanisms of coagulation induction by untargeted soluble tissue factor in vivo. Combination treatments including soluble tissue factor might represent an alternative vascular targeting approach for the treatment of malignant tumors.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Coagulation / drug effects*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Drug Therapy, Combination
  • Embolization, Therapeutic / methods*
  • Enzyme Activation / drug effects
  • Factor Xa / biosynthesis
  • Humans
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / pharmacology
  • Lipopolysaccharides / therapeutic use*
  • Lymphoma, Non-Hodgkin / blood
  • Lymphoma, Non-Hodgkin / therapy*
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Solubility
  • Surface Plasmon Resonance
  • Teratocarcinoma / blood supply
  • Teratocarcinoma / therapy*
  • Thromboplastin / administration & dosage
  • Thromboplastin / genetics
  • Thromboplastin / pharmacology
  • Thromboplastin / therapeutic use*
  • Tumor Necrosis Factor-alpha / analysis
  • Xenograft Model Antitumor Assays

Substances

  • Lipopolysaccharides
  • Peptide Fragments
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide, E coli O55-B5
  • Thromboplastin
  • Factor Xa